Optomed Oyj Class A · OMXHEX:OPTOMED
Optomed Oyj Class A — Investor Presentation (April 2022)
17 slides from Optomed Oyj Class A's investor presentation, April 2022
Slide 1: Optomed in Brief
Optomed IR presentation April 2022 Optomed in Brief
Slide 2: Global megatrends increasing demand
Global megatrends increasing demand Aging population Diabetes growing AI Prevalence of serious eye Technological advances in Diabetic Retinopathy (causing vision loss) diseases (causing vision artificial intelligence enable affects ~35% of all diabetics but can be loss) increase strongly faster diag
Slide 3: The prevalence of eye diseases is expected to increase rapidly
The prevalence of eye diseases is expected to increase rapidly which will again increase the need for screening Diabetic retinopathy Glaucoma AMD 463 M at risk. 895 M over 60 years old at risk. 604 M over 65 years old at risk. The leading cause of vision loss in adults. Prevalence increases by age.
Slide 4: Globally, there are only <250 000 eye doctors and the geographical dispersion is high
Globally, there is only <250 000 eye doctors and the geographical dispersion is high Resnikoff S, Lansingh VC, Washburn L, et al British Journal of Ophthalmology 2020;104:588-592. → Traditional screening methods are not sufficiently scalable to address the need
Slide 5: Transition from traditional desktop cameras to AI integrated handheld cameras has started
Transition from traditional desktop cameras to AI integrated handheld cameras has started Optomed’s handheld Traditional equipment …together with AI camera… • Large initial investments • Cost efficient • Saves eye doctor • Space constrains • For the use of all healthcare resources and lowers • For p
Slide 6: AI to increase the pace of transition towards primary care especially in the US
AI to increase the pace of transition towards primary care especially in the US The number of primary care doctors is significantly higher than the number of eye doctors (USA 246 0001 vs. 24 0002) Primary Care The reimbursement code for the screening of diabetic retinopathy using artificial intellig
Slide 7: Optomed is the leading handheld fundus camera manufacturer
Optomed is the leading handheld fundus camera manufacturer Established 2004, HQ and product development in Oulu, Finland Revenue 15 MEUR Over 60 distributors in 50 countries; several OEM partners Several AI partnerships e.g.. AEYE Health Ltd, Eyenuk Inc, EyRIS Pte. Ltd. Office Outsourced manufacturi
Slide 8: Optomed's current Product Portfolio
Optomed’s current Product Portfolio Volk Haag-Streit Optomed Smartscope Picture Plus Topcon Zeiss Optomed Optomed Optomed Fundus Aurora IQ PRO & Prestige Signal Visuscout Module 300 Polaris Halo E-Safe Optomed Avenue Avenue Screen Avenue Archive Avenue Avenue AI Avenue Sync Optomed Screen is a workf
Slide 9: Our latest handheld fundus camera
• Our latest handheld fundus camera • An easy-to-use tool for all healthcare professionals • AI for identifying diabetic retinopathy › Later suspected AMD and glaucoma • Results can be read from the camera screen in seconds → Speeds-up the screening process → Increases the coverage
Slide 10: FY 2021 highlights: clinical trial completed, OEM and North America strong
1. The Clinical Trial was completed FY 2021 FY 2020 Change Revenue 14,850 13,011 14.1% OEM channel, North American and 2. G European markets performed well Gross margin1 71.1% 68.8% +230 bps Adjusted EBITDA -2,002 -733 -173.2% China: strong growth during H1 but no 3. deliveries to China in H2 Cash a
Slide 11: Clinical Trial
Clinical Trial • 91.9% sensitivity • 93.6% specificity • 99+% imageability • Only a single image per eye Optomed and AEYE Health are seeking FDA clearance for the solution CAUTION - Investigational device. Limited by United States law to investigational use.
Slide 12: New US Business Model – Subscription
New US Business Model – Subscription Complete Solution Business Model Customer Benefits From product sales to complete screening solutions with diagnosis Solution leased, not No initial investments sold Only monthly rental fee Excellent clinical results, Fixed annual 91.9% sensitivity, subscription
Slide 13: Optomed's Artificial Intelligence
Optomed’s Artificial Intelligence 2021 Near-term future Future opportunities Eye-diseases Expansion to other diseases Preventive health-check in primary care Diabetic Retinopathy, age-related All eye disorders, neurological Eye disease, neurological disorders, macular degeneration (AMD), disorders,
Slide 14: Optomed's growth strategy – status update
Optomed’s growth strategy – status update Growth in existing markets and Expansion into new customer segments Focus on bringing new products and entering geographical new solutions to the market markets • Building of sales and distribution • Aurora IQ, the first fundus camera that • Optomed USA esta
Slide 15: Tel: +358 20 741 3380 • investors@optomed.com
Optomed Plc. Yrttipellontie 1, 90230 Oulu, Finland Tel: +358 20 741 3380 • investors@optomed.com www.optomed.com
Slide 16: Revenue and Gross profit
1-12/2021 1-12/2020 Change Revenue 14,850 13,011 14.1% Gross profit 1) 10,558 8,955 17.9% Gross margin 2) 71.1% 68.8% +230 bps Adjusted EBITDA -2,002 -733 -173.2% Adjusted EBITDA margin -13.5% -5.6% -790 bps Net profit/ loss -4,249 -3,177 -33.8% Earnings per share -0.32 -0.24 -32.0% Cash flow from o
Slide 17: Balance sheet
• Balance sheet 31/12 2021 31/12 2020 Balance sheet ASSETS Goodwill 4,256 4,256 Development costs 6,338 5,667 • Equity ratio of 58.8 (64.6) percent Other intangible assets 2,380 2,831 Total intangible assets 12,975 12,753 • Total borrowings of EUR 7.0 (6.5) Total tangible assets 1,651 1,535 million.